February 1, 2017Open Access

Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In this trial involving patients with advanced heart failure who were ineligible for heart transplantation, a small, intrapericardial, centrifugal-flow LVAD was found to be noninferior to an axial-flow LVAD with respect to survival free from disabling stroke or device removal for malfunction or failure. (Funded by HeartWare; ENDURANCE ClinicalTrials.gov number, NCT01166347 .).

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Rogers et al. (Wed,) studied this question.

synapsesocial.com/papers/69dd674a7808b00a4799d9ea https://doi.org/https://doi.org/10.1056/nejmoa1602954

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial2013 · 460 citations
2Results of the Destination Therapy Post-Food and Drug Administration Approval Study With a Continuous Flow Left Ventricular Assist Device2014 · 242 citations
3What is the truth behind pump thrombosis in the HeartMate II device? A National Heart, Lung, and Blood Institute perspective based on data from the Interagency Registry for Mechanically Assisted Circulatory Support2015 · 17 citations
4Use of a Continuous-Flow Device in Patients Awaiting Heart Transplantation2007 · 1,730 citations
5Executive Summary: Heart Disease and Stroke Statistics—2014 Update2014 · 1,405 citations

Me gusta

Guardar

Ver artículo completo